NICE restores parity between Alnylam and Akcea on rare diseaseNICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Share XNICE restores parity between Alnylam and Akcea on rare diseasehttps://pharmaphorum.com/news/nice-restores-parity-between-alnylam-and-akcea-on-rare-disease/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
